Phase I study of <scp>OPB</scp>‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), Kiyohiko Hatake(International University of Health and Welfare)
Cancer Science
April 23, 2015
Cited by 101


Related Papers